M223, a preclinical drug for inflammatory diseases, with potential milestone payments of $777.5M plus royalties.
Nuvation Bio gets $250M total funding for taletrectinib commercialization & pipeline; Syros to delist from Nasdaq on March 20 after January compliance warning ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback